DKK 1120.0
(-2.61%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -1099.00 DKK | 0.0% |
2022 | - DKK | 0.0% |
2021 | - DKK | 0.0% |
2020 | - DKK | 0.0% |
2019 | - DKK | 0.0% |
2018 | - DKK | 100.0% |
2017 | -4.84 Million DKK | 0.0% |
2016 | - DKK | 0.0% |
2015 | - DKK | 0.0% |
2014 | - DKK | 0.0% |
2013 | - DKK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - DKK | 0.0% |
2024 Q1 | - DKK | 100.0% |
2023 Q2 | - DKK | 0.0% |
2023 Q3 | - DKK | 0.0% |
2023 FY | -1099.00 DKK | 0.0% |
2023 Q1 | - DKK | 0.0% |
2023 Q4 | -1099.00 DKK | 0.0% |
2022 Q4 | - DKK | 0.0% |
2022 Q3 | - DKK | 100.0% |
2022 FY | - DKK | 0.0% |
2022 Q2 | -7.4 Million DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 Q3 | 1.00 DKK | 1718212958.42% |
2021 FY | - DKK | 0.0% |
2021 Q1 | - DKK | 0.0% |
2021 Q2 | - DKK | 0.0% |
2021 Q4 | - DKK | -100.0% |
2020 Q2 | -27.74 Million DKK | 0.0% |
2020 FY | - DKK | 0.0% |
2020 Q4 | - DKK | 0.0% |
2020 Q3 | - DKK | 100.0% |
2020 Q1 | - DKK | 0.0% |
2019 FY | - DKK | 0.0% |
2019 Q1 | - DKK | 100.0% |
2019 Q3 | - DKK | 100.0% |
2019 Q4 | - DKK | 0.0% |
2019 Q2 | -14.97 Million DKK | 0.0% |
2018 Q4 | -14.44 Million DKK | 0.0% |
2018 FY | - DKK | 100.0% |
2018 Q1 | - DKK | 100.0% |
2018 Q2 | -14.35 Million DKK | 0.0% |
2018 Q3 | - DKK | 100.0% |
2017 Q2 | -101.92 Million DKK | 0.0% |
2017 FY | -4.84 Million DKK | 0.0% |
2017 Q4 | -16.21 Million DKK | 0.0% |
2017 Q3 | - DKK | 100.0% |
2017 Q1 | - DKK | 100.0% |
2016 Q3 | - DKK | 0.0% |
2016 Q4 | -8.92 Million DKK | 0.0% |
2016 Q1 | - DKK | 0.0% |
2016 FY | - DKK | 0.0% |
2015 FY | - DKK | 0.0% |
2014 FY | - DKK | 0.0% |
2013 FY | - DKK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ALK-Abelló A/S | 1.42 Billion DKK | 100.0% |
Bavarian Nordic A/S | 1.64 Billion DKK | 100.0% |
Genmab A/S | 57 Million DKK | 100.002% |
Gubra A/S | -403.98 Million DKK | 100.0% |
Novo Nordisk A/S | 31.81 Billion DKK | 100.0% |
Pharma Equity Group A/S | 1000.00 DKK | 209.9% |
Zealand Pharma A/S | 7.93 Million DKK | 100.014% |